Cardiovascular diseases: a review of the Hispanic perspective. Awareness is the first step to action
Related Experiment Video
Updated: Aug 14, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
1University of Pittsburgh Medical Center, Cardiovascular Institute, Pittsburgh, PA 15213, USA. lopezcandalesa@msx.upmc.edu
Insights
Coronary heart disease (CHD) mortality has decreased due to fewer risk factors and heart attacks. However, Hispanic participation in cardiovascular clinical trials remains low, hindering understanding of their specific disease trends.
Area of Science:
- Cardiology
- Public Health
- Health Disparities
Background:
- Coronary heart disease (CHD) is a leading cause of death in US adults.
- Mortality rates for cardiovascular disease have declined globally since 1975.
- This decline is linked to reduced risk factors and myocardial infarction rates.
Purpose of the Study:
- To review Hispanic enrollment in major cardiovascular clinical trials.
- To identify reasons for observed participation levels.
- To propose strategies for improving Hispanic inclusion in research.
Main Methods:
- Literature review of cardiovascular clinical trials.
- Analysis of enrollment data focusing on Hispanic participants.
- Synthesis of existing research on risk factors and outcomes in diverse populations.
Main Results:
- Hispanic participation in cardiovascular clinical trials is suboptimal.
- Specific data on incidence and nature of risk factors in Hispanic populations are limited.
- Existing research highlights disparities in cardiovascular disease outcomes.
Conclusions:
- Low Hispanic participation limits understanding of cardiovascular disease in this demographic.
- Targeted strategies are needed to increase minority inclusion in clinical research.
- Addressing participation barriers is crucial for equitable cardiovascular healthcare.
Abstract:
Coronary heart disease is the leading cause of death in adults in the United States, accounting for about one-third of all deaths in subjects over age 35 (Thom et al., 1998). Mortality rates for cardiovascular disease and coronary heart disease in men and women and in blacks and whites have fallen in most countries by 24 to 28 percent since 1975, although the decline has slowed since 1990 (Kuulasmaa et al., 2000; McGovern et al., 1996; Capewell et al., 1999; Capewell et al., 2000; Cooper et al., 2000; McGovern et al., 2001; Gillum, 1994). This favorable trend is related partly to a decrease in the rate of fatal myocardial infarction (Gillum, 1987; Goldberg et al., 1988; Pashos et al., 1993; de Vreede et al., 1991), but it is also associated with a decline in the prevalence of risk factors for coronary artery disease (Gillium, 1994; Gillium 1987; Pearson, 1989). These risk factors strongly influence the severity of coronary atherosclerosis (Rhoads et al., 1978; Sorlie et al., 1981; Feinleib et al., 1979; Freedman et al., 1993; Reed and Yano, 1991), a major predictor of survival in patients with coronary disease (Humphries et al., 1974). These observations suggest that the decline in mortality from coronary artery disease is related to a parallel decline in coronary atherosclerosis. Despite great strides regarding the knowledge of coronary artery risk factors and some of its demographic aspects, the incidence and nature of each individual variable in certain ethnic and racial groups remain poorly defined. Over a decade ago the American Heart Association issued a statement regarding cardiovascular disease and stroke in racial minorities in the United States and urged for more participation of minority groups in research studies in order to assess their particular trends and outcomes (American Heart Association Medical/Scientific Statement, 1991). The purpose of this article is to review the current enrollment and participation of Hispanics in major clinical trials relating to cardiovascular disease and propose possible explanations for the observed results as well as suggestions to improve the shortcomings found.
More Related Videos
13:07Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
08:21Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans
Published on: July 21, 2023
Related Concept Videos
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Coronary Artery Disease I: Introduction
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management